Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-cash Items (2021 - 2023)

Historic Non-cash Items for Vistagen Therapeutics (VTGN) over the last 5 years, with Q1 2023 value amounting to $496257.0.

  • Vistagen Therapeutics' Non-cash Items rose 971.64% to $496257.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $496257.0, marking a year-over-year increase of 971.64%. This contributed to the annual value of $496257.0 for FY2023, which is 971.64% up from last year.
  • Per Vistagen Therapeutics' latest filing, its Non-cash Items stood at $496257.0 for Q1 2023, which was up 971.64% from $452309.0 recorded in Q1 2022.
  • Vistagen Therapeutics' 5-year Non-cash Items high stood at $10.7 million for Q1 2021, and its period low was $452309.0 during Q1 2022.
  • Its 3-year average for Non-cash Items is $3.9 million, with a median of $496257.0 in 2023.
  • As far as peak fluctuations go, Vistagen Therapeutics' Non-cash Items tumbled by 9578.54% in 2022, and later surged by 971.64% in 2023.
  • Over the past 3 years, Vistagen Therapeutics' Non-cash Items (Quarter) stood at $10.7 million in 2021, then plummeted by 95.79% to $452309.0 in 2022, then grew by 9.72% to $496257.0 in 2023.
  • Its Non-cash Items stands at $496257.0 for Q1 2023, versus $452309.0 for Q1 2022 and $10.7 million for Q1 2021.